Company: SVREW
Filing Date: 2025-03-21
Form Type: DRS
Source: 0001013762-25-001070
Chunk: 18

Company: SaverOne 2014 Ltd.
Filing Date: 2025-03-21
Form: DRS
Chunk 18
---

 involves a high degree of risk. See “Risk Factors” beginning on page 9 of this prospectus for a description of                          
 certain of the risks you should consider before investing in our securities.                                                            |
| Depositary   |     | The Bank of New York Mellon                                                                                                             |

<div align='center'>7</div>

| Nasdaq Capital Market symbol   |     | “SVRE” |
| Tel Aviv Stock Exchange symbol |     | “SVRE” |

The number of Ordinary Shares to be outstanding after this offering is based on 741,152,046 Ordinary Shares outstanding as of March 19, 2025. The number of Ordinary Shares referred to above to be outstanding after this offering and, unless otherwise indicated, the other information in this prospectus, excludes as of such date:

| ● | 1,752,917 Ordinary Shares                                                                                                   
 issuable upon exercise of options outstanding ‌under the SaverOne 2014 Ltd. 2015 Share Incentive Plan, or the 2015 Plan, at 
 a weighted average exercise price of NIS 5.56 (approximately $1.53) per share;                                              |

| ● | 405,000 restricted Ordinary                    
 Shares units outstanding ‌under the 2015 Plan; |

| ● | 3,347,083 Ordinary Shares                         
 reserved for future issuance under our 2015 Plan; |

| ● | 16,383,410 Ordinary Shares                                                                                                 
 issuable upon the exercise of warrants sold in our initial public offering, or IPO, in the United States in June 2022; and |

| ● | 787,550 Ordinary Shares                                                                                                          
 issuable upon the exercise of warrants granted to the underwriters in connection with our IPO in the United States in June 2022. |

Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to no exercise of the options and warrants, as described above.

<div align='center'>8

RISK FACTORS</div>

Investing in our securities involves a high degree of risk. You should carefully consider the risks described in our 2024 Annual Report which are incorporated by reference herein, as well as the financial and other information included in this prospectus or incorporated by reference in this prospectus, including our financial statements and related notes, before you decide to purchase our securities. If any of the following risks occur, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that case, the